Dunad: Expanding protein degradation beyond E3 ligase

Dunad has emerged from a year in stealth with a platform that the U.K. company believes could offer a simpler mechanism for degrading protein targets. 

One of the primary differentiating features of Dunad Therapeutics Ltd.’s protein degradation platform is that it doesn’t conform to the E3 ligase pathway that many other degradation technologies rely on...